

If a conflict arises between a Clinical Payment and Coding Policy ("CPCP") and any plan document under which a member is entitled to Covered Services, the plan document will govern. If a conflict arises between a CPCP and any provider contract pursuant to which a provider participates in and/or provides Covered Services to eligible member(s) and/or plans, the provider contract will govern. "Plan documents" include, but are not limited to, Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents. BCBSOK may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case. BCBSOK has full and final discretionary authority for their interpretation and application to the extent provided under any applicable plan documents.

Providers are responsible for submission of accurate documentation of services performed. Providers are expected to submit claims for services rendered using valid code combinations from Health Insurance Portability and Accountability Act ("HIPAA") approved code sets. Claims should be coded appropriately according to industry standard coding guidelines including, but not limited to: Uniform Billing ("UB") Editor, American Medical Association ("AMA"), Current Procedural Terminology ("CPT®"), CPT® Assistant, Healthcare Common Procedure Coding System ("HCPCS"), ICD-10 CM and PCS, National Drug Codes ("NDC"), Diagnosis Related Group ("DRG") guidelines, Centers for Medicare and Medicaid Services ("CMS") National Correct Coding Initiative ("NCCI") Policy Manual, CCI table edits and other CMS guidelines.

Claims are subject to the code edit protocols for services/procedures billed. Claim submissions are subject to claim review including but not limited to, any terms of benefit coverage, provider contract language, medical policies, clinical payment and coding policies as well as coding software logic. Upon request, the provider is urged to submit any additional documentation.

Preventive Services Policy

Policy Number: CPCP006

Version: 1.0

Enterprise Clinical Payment and Coding Policy Committee Approval Date: September 26, 2022

Effective Date: October 1, 2022

Definitions

The following acronyms have been utilized throughout this reimbursement policy

ACIP: Advisory Committee on Immunization Practices
CDC: Centers for Disease Control and Prevention
FDA: United States Food and Drug Administration
HRSA: Health Resources and Services Administration

PPACA: Patient Protection and Affordable Care Act of 2010

USPSTF: United States Preventive Services Task Force

Description

Section 2713 of the Patient Protection and Affordable Care Act (PPACA) mandates that private health plans provide coverage of preventive services issued by the following agencies: The United States Preventive Services Task Force (USPSTF), the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC), and the Health Resources and Service Administration (HRSA) with respect to women's guidelines and guidelines for infants, children, and adolescents. These services are available at no cost-share when obtained by a member covered under a non-grandfathered plan. This applies to members belonging to individual, small group, large group, and self-insured plans. There is no copay, deductible or coinsurance, even if the individual or family deductible or out-of-pocket maximum has not been met as long as the member utilizes a provider in the plan's network.

Preventive care or preventive medicine refers to measures or services taken to promote health and early detection/prevention of disease(s) and injuries rather than treating them and/or curing them. Preventive care may include, but are not limited to, examinations and screening tests tailored to an individual's age, health, and family history.

PPACA does not mandate that preventive services be covered at no member cost-share when obtained out-of-network. Members that obtain preventive services out of their network will be subject to copay, deductible, and coinsurance.

Grandfathered plans are plans that have been in existence prior to March 23, 2010 and are exempt from the requirement of providing preventive services at no member cost share. Grandfathered plans have the opportunity to elect providing coverage of preventive services at no member cost share but are not required to do so.

The USPSTF applies a letter grade for each of the recommendations that are released. The grade definitions for USPSTF recommendations released after July 2012 are as follows https://www.uspreventiveservicestaskforce.org/Page/Name/grade-definitions

Following the recommendation of the USPTF coverage of Grade "A" and "B" recommendations is provided at no member cost share for members with a non-grandfathered health plan. The USPTF published recommendations can be found at

https://www.uspreventiveservicestaskforce.org/BrowseRec/Index

Grade	Definition
Α	The USPSTF recommends the service. There is high
	certainty that the net benefit is substantial.
В	The USPSTF recommends the service. There is high
	certainty that the net benefit is moderate or there is
	moderate certainty that the net benefit is moderate to
	substantial.
С	The USPSTF recommends selectively offering or providing
	this service to individual patients based on professional
	judgment and patient preferences. There is at least
	moderate certainty that the net benefit is small.
D	The USPSTF recommends against the service. There is
	moderate or high certainty that the service has no net
	benefit or that the harms outweigh the benefits.
1	The USPSTF concludes that the current evidence is
•	insufficient to assess the balance of benefits and harms of
	the service. Evidence is lacking, of poor quality, or
	conflicting, and the balance of benefits and harms cannot
	be determined.

The ACIP publishes recommendations on the safe utilization of vaccines. ACIP's recommendations include immunization schedules for children and adolescents as well as adults which can be found at https://www.cdc.gov/vaccines/schedules/hcp/index.html. Travel Immunizations such as, but not limited to, Japanese Encephalitis, Typhoid, Yellow Fever, and Small Pox are excluded from Preventive Service coverage. Other excluded vaccinations include Anthrax, Bacille Calmette Guerin for Tuberculosis (BCG), and Rabies which are not required by PPACA. Immunizations should be administered in accordance with the ACIP Recommended Child and Adult Immunization Schedules or in accordance with state law or regulations.

HRSA releases Women's Preventive Services guidelines that are aimed at improving women's health by recommending certain preventive services that should be obtained in the clinical setting. HRSA's list of recommendations can be obtained at https://www.hrsa.gov/womensguidelines2016/index.html

HRSA endorses preventive guidelines established by the American Academy of Pediatrics for the health and well-being of infants, children, and adolescents. These recommendations are referred to as Bright Futures and the comprehensive list of Bright Future's recommendations can be found at https://www.aap.org/en-us/Documents/practicet periodicity AllVisits.pdf

Reimbursement Information:

Certain preventive care services may be considered eligible for coverage under the member's benefit plan as required by PPACA and/or an applicable state mandate. In general, these services include, but are not limited to, screenings, immunizations, and other types of care as recommended by the United States Federal Government.

These services are not subject to application of cost-sharing such as co-payments, co-insurance or deductibles when they are considered eligible for coverage and are provided by a network provider. In order for preventive claims to process at the preventive level with no member cost share, the claim must include a preventive diagnosis code, a preventive procedure code, meet medical policy review criteria, and fall within the guidelines issued by the USPSTF, ACIP, HRSA, or Bright Futures.

Health care providers (facilities, physicians and other health care professionals) are expected to exercise independent medical judgement in providing care to patients. This Preventive Services Reimbursement policy is not intended to impact care decisions or medical practice.

The following grid provides a list of the recommendations released by the USPSTF, ACIP, HRSA, or Bright Futures along with the corresponding procedure codes and diagnosis codes deemed to be preventive.

USPSTF Recommendations:

Service:	Procedure	Additional
	Code(s):	Reimbursement Criteria:
Abdominal Aortic Aneurysm Screening	76706	Procedure code 76706 is reimbursable as preventive when
USPSTF "B" Recommendation December		submitted with one of the
<u>2019</u>		following: Z13.6, Z87.891, Z72.0,
The USPSTF recommends 1-time screening		Z00.00, Z00.01, F17.210, F17.200
for abdominal aortic aneurysm (AAA) with		
ultrasonography in men aged 65 to 75 years		
who have ever smoked.		
Unhealthy Alcohol Use in Adolescents and	99385, 99386, 99387,	Payable with a diagnosis code in
Adults: Screening and Behavioral Counseling	99395, 99396, 99397,	Diagnosis List 1
Interventions	99408, 99409,	
	G0396, G0397,	
USPSTF "B" Recommendation November	G0442, G0443	
2018		
The USPSTF recommends screening for		
unhealthy alcohol use in primary care settings		
for adults 18 years or older, including		
pregnant women, and providing persons		
engaged in risky or hazardous drinking with		
brief behavioral counseling interventions to		
reduce unhealthy alcohol use.		
Aspirin Use to Prevent Preeclampsia and		For details about pharmacy
Related Morbidity and Mortality: Preventive		benefit coverage, contact the
Medication		number on the patient's BCBS
		member card. A patient's
USPSTF "B" Recommendation September		pharmacy benefit may be
<u>2021</u>		managed by a company other
The USPSTF recommends the use of low-dose		than BCBS.
aspirin (81 mg/day) as preventive medication		

after 12 weeks of gestation in persons who are at high risk for preeclampsia. Asymptomatic Bacteriuria in Adults Screening USPSTF "B" Recommendation September 2019 The USPSTF recommends screening for	81007, 87086, 87088	Coverage includes generic aspirin 81 mg tablets with a prescription. Payable with a Pregnancy Diagnosis
asymptomatic bacteriuria using urine culture in pregnant persons. BRCA-Related Cancer Risk Assessment,	81212, 81215, 81216,	These services are subject to
USPSTF "B" Recommendation August 2019 USPSTF recommends that primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with breast cancer susceptibility 1 and 2 (BRCA1/2) gene mutations with an appropriate brief familial risk assessment tool. Women with a positive result on the risk assessment tool should receive genetic counseling and, if indicated after counseling, genetic testing.	81212, 81213, 81216, 81217, 81162, 81163, 81164, 81165, 81166, 81167, 96040, 99385, 99386, 99387, 99395, 99396, 99397, 99401, 99402, 99403, 99404, G0463, S0265, 81307, 81308	These services are subject to Medical Policy and prior authorization may be required Procedure codes 81212, 81215-81217, 81162-81167, 81307 and 81308 are reimbursable as preventive when submitted with one of the following primary diagnosis codes: Z80.3, Z80.41, Z85.3, Z85.43 Procedure code 96040 is reimbursable as preventive when submitted with one of the following primary diagnosis codes: Z80.3 or Z80.41 All other procedure codes for BRCA are payable with a diagnosis in Diagnosis List 1
Breast Cancer Medications for Risk Reduction		in Diagnosis List 1 For details about pharmacy benefit coverage, contact the
USPSTF "B" Recommendations September 2019 The USPSTF recommends that clinicians offer to prescribe risk-reducing medications, such as tamoxifen, raloxifene, or aromatase		number on the patient's BCBS member card. A patient's pharmacy benefit may be managed by a company other than BCBS.
inhibitors, to women who are at increased risk for breast cancer and at low risk for adverse medication effects.		Coverage includes generic anastrozole 1 mg, raloxifene hcl 60 mg, and tamoxifen citrate 10 and 20 mg tablets when used for prevention in members ages 35 and over with a prescription.

Broast Cancar Screening	77061 77062 77062	Payable with a diagnosis code in
Breast Cancer Screening	77061, 77062, 77063, 77067	Payable with a diagnosis code in Diagnosis List 1
USPSTF "B" Recommendation January 2016	77007	Diagnosis List I
The USPSTF recommends biennial screening		
mammography for women aged 50 to 74		
years. Refer also to HRSA's 'Breast Cancer Screening		
for Women at Average Risk' recommendation		
Jor Women at Average Kisk Tecommendation		
Breastfeeding Primary Care Interventions	99401, 99402, 99403,	Electric breast pumps limited to
Journal of the state of the sta	99404, 99411, 99412	one per benefit period. Hospital
USPSTF "B" Recommendation October 2016	33 10 1, 33 111, 33 111	Grade breast pumps are limited to
The USPSTF recommends providing	A4281, A4282,	rental only.
interventions during pregnancy and after	A4283, A4284,	Tented only.
birth to support breastfeeding.	A4285, A4286,	Additional reimbursement
birti to support breastreeding.	E0602, E0603, E0604,	information available within the
Refer also to HRSA's 'Breastfeeding Services	S9443	"Breastfeeding Equipment and
and Supplies' recommendation	33443	Supplies"
Cervical Cancer Screening	99385, 99386, 99387,	Payable with a diagnosis code in
Control cancer serecining	99395, 99396,99397	Diagnosis List 1
USPSTF "A" Recommendation August 2018	33333, 33330,33337	Diagnosis List I
The USPSTF recommends screening for	G0101, 88141,	
cervical cancer every 3 years with cervical	88142, 88143, 88147,	
cytology alone in women aged 21 to 29 years.	88148, 88150, 88152,	
For women aged 30 to 65 years, the USPSTF	88153, 88155, 88164,	
recommends screening every 3 years with	88165, 88166, 88167,	
cervical cytology alone, every 5 years with	88174, 88175,	
high-risk human papillomavirus (hrHPV)	G0123, G0124,	
testing alone, or every 5 years with hrHPV	G0123, G0124, G0141, G0143,	
testing in combination with cytology	G0144, G0145,	
(cotesting).	G0147, G0148,	
(60.655.118).	P3000, P3001,	
Refer also to HRSA's 'Cervical Cancer	Q0091, 87623,	
Screening' recommendation	87624, 87625, S0610,	
Servering recommendation	S0612, 0500T,0096U,	
	0354U	
Chlamydia Screening	86631, 86632, 87110,	Payable with a diagnosis code in
,	87270, 87320, 87490,	Diagnosis List 1
USPSTF "B" Recommendations September	87491, 87492, 87801,	3
2021	87810	
The USPSTF recommends screening for		
chlamydia in sexually active women age 24		
years and younger and in women 25 years or		
older who are at increased risk for infection.		
Colorectal Cancer Screening	82270, 82274,	Certain colorectal cancer
	G0328, 44388,	screening services may be subject
USPSTF "A" Recommendation May 2021	44389,44392, 44394,	

The USPSTF recommends screening for	44401, 44404,	to medical policy criteria and may	
colorectal cancer in all adults aged 50 to 75	45378,45380,	require prior authorization	
years.	45381,45384,		
	45385,45388, G0105,	Modifier 33 or PT may be applied	
USPSTF "B" Recommendation May 2021	G0106, G0120,	Payable with a diagnosis in	
The USPSTF recommends screening for	G0121, G0122,45330,	Diagnosis List 1	
colorectal cancer in adults aged 45 to 49	45331, 45333,45335,		
years.	45338,45346, 74263,	In the instance that a polyp is	
· · · · · · · · · · · · · · · · · ·	88304, 88305,	removed during a preventive	
The risks and benefits of different screening	G0104, 99202, 99203, 99204, 99205,	colonoscopy, the colonoscopy as well as the removal of the polyp	
methods vary.	99203, 99204, 99203,	and the labs and services related	
	99214, 99215, 99417,	to the colonoscopy are	
	S0285, 00812, 00813	reimbursable at the preventive	
	81528	level.	
	81328	level.	
		Sedation procedure codes 99152,	
		99153, 99156, 99157, and G0500	
		will process at the preventive level	
		when billed with a diagnosis of	
		Z12.11 or Z12.12	
		Procedure code 74263 is	
		reimbursable at the preventive	
		level when billed with one of the	
		following three diagnosis codes:	
		Z00.00, Z12.11, Z12.12	
		Procedure code 81528 is	
		reimbursable at the preventive	
		level when billed with Z12.11 or	
		Z12.12 for out of network claims.	
		212.12 for out of fictwork claims.	
		For details about pharmacy	
		benefit coverage, contact the	
		number on the patient's BCBS	
		member card. A patient's	
		pharmacy benefit may be	
		managed by a company other	
		than BCBS.	
		Coverage includes governing	
		Coverage includes generic peg	
		3350-kcl-na bicarb-nacl-na sulfate	
		solutions for members ages 45 and over with a prescription.	
Congenital Hypothyroidism Screening	84443, 99381, S3620	and over with a prescription.	
3			
USPSTF "A" Recommendation March 2008			

The USPSTF recommends screening for		
congenital hypothyroidism in newborns.		
Dental Caries in Children from Birth Through	99188	For details about pharmacy
Age 5 Years Screening	33100	benefit coverage, contact the
, age o realis seriesg		number on the patient's BCBS
USPSTF "B" Recommendation December		member card. A patient's
2021		pharmacy benefit may be
The USPSTF recommends that primary care		managed by a company other
clinicians prescribe oral fluoride		than BCBS.
supplementation starting at age 6 months for		than bebs.
children whose water supply is deficient in		
fluoride.		Prescription required for both
nuonue.		over-the-counter (OTC) and
USPSTF "B" Recommendation December		prescription medications.
2021		prescription medications.
The USPSTF recommends that primary care		
clinicians apply fluoride varnish to the		
primary teeth of all infants and children		
starting at the age of primary tooth eruption.		
starting at the age of primary tooth eruption.		
Depression Screening Adults	99385, 99386, 99387,	Payable with a diagnosis code in
- Spread of Comments	99395, 99396, 99397,	Diagnosis List 1
USPSTF "B" Recommendation January 2016	96160, 96161,	2.000.00.00
The USPSTF recommends screening for	G0444, 96127	Procedure code 96127 is only
depression in the general adult population,		reimbursable at the preventive
including pregnant and postpartum women.		level when billed with a diagnosis
Screening should be implemented with		of Z00.129, Z13.31, Z13.32,
adequate systems in place to ensure accurate		Z13.39, Z13.41, or Z13.42
diagnosis, effective treatment, and		, ,
appropriate follow-up.		
Depression in Children and Adolescents	99384, 99385, 99394,	Payable with a diagnosis in
Screening	99395, 96127, G0444	Diagnosis List 1
USPSTF "B" Recommendation February 2016		Procedure code 96127 is only
The USPSTF recommends screening for major		reimbursable at the preventive
depressive disorder (MDD) in adolescents		level when billed with a diagnosis
aged 12 to 18 years. Screening should be		of Z00.129, Z13.31, Z13.32,
implemented with adequate systems in place		Z13.39, Z13.41, or Z13.42
to ensure accurate diagnosis, effective		
treatment, and appropriate follow-up.		
Refer also to Bright Futures 'Depression		
Screening' recommendation		
Screening recommendation		
Falls Prevention in Community Dwelling	97110, 97112, 97116,	Procedure codes 97110, 97112,
Older Adults: Interventions	97150, 97161, 97162,	97116, 97150, 97161, 97162,
	1 2 . 100, 3 . 101, 3 . 102,	5. 220, 5. 250, 5. 201, 5. 202,

	T	T
	97163, 97164, 97165,	97163, 97164, 97165, 97166,
USPSTF "B" Recommendation April 2018 The	97166, 97167, 97168,	97167, 97168, and 97530
USPSTF recommends exercise interventions	97530	reimbursable with a diagnosis of
to prevent falls in community-dwelling adults		Z91.81
aged 65 years or older who are at increased		
risk for falls.		
Folic Acid for the Prevention of Neural Tube		For details about pharmacy
Defects: Preventive Medication		benefit coverage, contact the
LICECTE "A" Decompose detical logues a 2017		number on the patient's BCBS
USPSTF "A" Recommendation January 2017 The USPSTF recommends that all women who		member card. A patient's
		pharmacy benefit may be
are planning or capable of pregnancy take a		managed by a company other than BCBS.
daily supplement containing 0.4 to 0.8 mg (400 to 800 µg) of folic acid.		tildii BCB3.
(400 to 800 μg) of folic acid.		Prescription required for both
		over-the-counter (OTC) and
		prescription medications.
Gestational Diabetes: Screening	36415, 82947, 82948,	Payable with a pregnancy
destational Diabetes. Screening	82950, 82951, 82952,	diagnosis
USPSTF "B" Recommendation August 2021	83036	ulagilosis
The USPSTF recommends screening for	03030	
gestational diabetes in asymptomatic		
pregnant persons at 24 weeks of gestation or		
after.		
arter.		
Refer also to HRSA's 'Gestational Diabetes'		
recommendation		
Gonorrhea Screening	87801, 87590, 87591,	Payable with a diagnosis code in
•	87592, 87850	Diagnosis List 1
USPSTF "B" Recommendation September		_
<u>2021</u>		
The USPSTF recommends screening for		
gonorrhea in sexually active women age 24		
years and younger and in women 25 years or		
older who are at increased risk for infection.		
Healthy Diet and Physical Activity for	99385, 99386, 99387,	
Cardiovascular Disease Prevention in Adults	99395, 99396, 99397,	
with Cardiovascular Risk Factors: Behavioral	G0438, G0439,	
Counseling	G0446, S9452, S9470,	
	97802, 97803, 97804,	
<u>USPSTF "B" Recommendation November</u>	G0270, G0271,	
<u>2020</u>	99078, 99401, 99402,	
The USPSTF recommends offering or referring	99403, 99404, 99411,	
adults with cardiovascular disease risk factors	99412, G0473	
to behavioral counseling interventions to		
promote a healthy diet and physical activity.		

Healthy Weight and Weight Gain in Pregnancy: Behavioral Counseling Interventions USPSTF "B" Recommendation May 2021 The USPSTF recommends that clinicians offer pregnant persons effective behavioral counseling interventions aimed at promoting healthy weight gain and preventing excess gestational weight gain in pregnancy.	99384, 99385, 99386, 99394, 99395, 99396, 99401, 99402, 99403, 99404, 99411, 99412	
Hepatitis B in Pregnant Women Screening USPSTF "A" Recommendation July 2019 The USPSTF recommends screening for hepatitis B virus (HBV) infection in pregnant women at their first prenatal visit.	80055, 86706, 87340, 87341, 80074, 80076, G0499, 36415	Payable with a pregnancy diagnosis, or a diagnosis code in Diagnosis List 1
USPSTF "B" Recommendation December 2020 The USPSTF recommends screening for hepatitis B virus (HBV) infection in adolescents and adults at increased risk for infection.	80055, 80074, 80076, 86706, 87340, 87341	Payable with a diagnosis code in Diagnosis List 1
Hepatitis C Screening USPSTF "B" Recommendation March 2020 The USPSTF recommends screening for hepatitis C virus infection in adults aged 18 to 79 years.	86803, 86804, G0472	Payable with a pregnancy diagnosis, or a diagnosis code in Diagnosis List 1
High Blood Pressure Screening in Adults USPSTF "A" Recommendation April 2021 The USPSTF recommends screening for high blood pressure in adults aged 18 years or older. The USPSTF recommends obtaining measurements outside of the clinical setting for diagnostic confirmation before starting treatment.	93784, 93786, 93788, 93790, 99385, 99386, 99387, 99395, 99396, 99397, 99473, 99474	Procedure codes 93784, 93786, 93788, 93790, 99473, and 99474 are reimbursable at the preventive level when billed with one of the following diagnosis codes: R03.0, R03.1, Z01.30, Z01.31

Human Immunodeficiency Virus (HIV) Infection Prevention Drug Pre-exposure Prophylaxis (PrEP) USPSTF "A" Recommendation June 2019 The USPSTF recommends that clinicians offer preexposure prophylaxis (PrEP) with effective antiretroviral therapy to persons who are at high risk of HIV acquisition. See the Clinical Considerations section for information about identification of persons at high risk and selection of effective antiretroviral therapy.		Baseline and monitoring services related to PrEP medication are reimbursable at the reimbursable at the preventive level. Details about benefit coverage contact the number on the patient's BCBS card. For details about pharmacy benefit coverage, contact the number on the patient's BCBS member card. A patient's pharmacy benefit may be managed by a company other than BCBS. Coverage includes brand and/or generic Truvada (emtricitabine/tenofovir disoproxil fumarate) 200-300 mg tablets when used for prevention with a prescription. Refer to the member's drug list for coverage details.
Human Immunodeficiency Virus (HIV) Infection Screening for Non-Pregnant Adolescents and Adults USPSTF "A" Recommendation June 2019 The USPSTF recommends that clinicians screen for HIV infection in adolescents and adults aged 15 to 65 years. Younger adolescents and older adults who are at increased risk should also be screened. Refer also to HRSA's 'HIV Screening and Counseling' recommendation Refer also to Bright Future's 'STI/HIV Screening' recommendation	87389, 87390, 87391, 87806, G0432, G0433, G0435	Payable with a diagnosis code in Diagnosis List 1

Human Immunodeficiency Virus (HIV) Infection Screening for Pregnant Women USPSTF "A" Recommendation June 2019 The USPSTF recommends that clinicians screen all pregnant persons, , including those who present in labor or at delivery whose HIV status is unknown. Refer also to HRSA's 'HIV Screening and Counseling' recommendation Refer also to Bright Future's 'STI/HIV Screening' recommendation	36415, 80081, 86689, 86701, 86702, 86703, 87389, 87390, 87391, 87806, G0432, G0433, G0435, G0475	Payable with a pregnancy diagnosis or a diagnosis code in Diagnosis List 1
Intimate Partner Violence, Elder Abuse, and Abuse of Vulnerable Adults Screening USPSTF "B" Recommendation October 2018 The U.S. Preventive Services Task Force (USPSTF) recommends that clinicians screen for intimate partner violence in women of reproductive age and provide or refer women who screen positive to ongoing support services. Latent Tuberculosis Infection Screening	99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, 99384, 99385, 99386, 99387, 99394, 99395, 99396, 99397, 99401, 99402, 99403, 99404, 99411, 99412, 99417, S0610, S0612, S0613	Payable with a diagnosis code in Diagnosis List 1 Payable with a diagnosis code in Diagnosis List 1
USPSTF "B" Recommendation September 2016 The USPSTF recommends screening for latent tuberculosis infection (LTBI) in populations at increased risk.		
Lung Cancer Screening USPSTF "B" Recommendation March 2021 The USPSTF recommends annual screening for lung cancer with low-dose computed tomography (LDCT) in adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery.	G0296, 71271	Subject to medical policy criteria and may require preauthorization Eff. 01/01/2021 procedure code 71271 is reimbursable at the preventive level if it meets medical policy criteria and is billed with one of the following diagnosis codes: F17.200, F17.201, F17.210, F17.211, F17.220, F17.221, F17.290, F17.291, Z12.2, Z87.891

Water transfer for a set Obertin Bulletind	07002 07002 07004	
Weight Loss to Prevent Obesity-Related	97802, 97803, 97804,	
Morbidity and Mortality in Adults:	99385, 99386, 99387,	
Behavioral Interventions	99395, 99396, 99397,	
LICECTE (ID)	99401, 99402, 99403,	
USPSTF "B" Recommendation September	99404, 99411, 99412,	
2018	99078, G0447, G0473	
The USPSTF recommends that clinicians offer		
or refer adults with a body mass index (BMI)		
of 30 or higher (calculated as weight in		
kilograms divided by height in meters		
squared) to intensive, multicomponent behavioral interventions.		
benavioral interventions.		
Obesity in Children and Adolescents	97802, 97803, 99383,	
Screening	99384, 99385, 99393,	
	99401, 99402, 99403,	
USPSTF "B" Recommendation June 2017	99404, 99411, 99412,	
The USPSTF recommends that clinicians	G0446, G0447,	
screen for obesity in children and adolescents	G0473	
6 years and older and offer them or refer		
them to comprehensive, intensive behavioral		
interventions to promote improvement in		
weight status.		
Ocular Prophylaxis for Gonococcal		When billed under inpatient
		medical
Ophthalmia Neonatorum Preventive		Illeuicai
Ophthalmia Neonatorum Preventive Medication		ineuicai
1 · · ·		medical
Medication		medical
Medication USPSTF "A" Recommendation January 2019		ineuicai
Medication USPSTF "A" Recommendation January 2019 The USPSTF recommends prophylactic ocular		ineuicai
Medication USPSTF "A" Recommendation January 2019 The USPSTF recommends prophylactic ocular topical medication for all newborns to	76977, 77078, 77080,	Payable with a diagnosis code in
Medication USPSTF "A" Recommendation January 2019 The USPSTF recommends prophylactic ocular topical medication for all newborns to prevent gonococcal ophthalmia neonatorum.	76977, 77078, 77080, 77081, 78350, 78351, G0130,	
Medication USPSTF "A" Recommendation January 2019 The USPSTF recommends prophylactic ocular topical medication for all newborns to prevent gonococcal ophthalmia neonatorum. Osteoporosis Screening	77081, 78350, 78351,	Payable with a diagnosis code in
Medication USPSTF "A" Recommendation January 2019 The USPSTF recommends prophylactic ocular topical medication for all newborns to prevent gonococcal ophthalmia neonatorum. Osteoporosis Screening USPSTF "B" Recommendation June 2018	77081, 78350, 78351,	Payable with a diagnosis code in
Medication USPSTF "A" Recommendation January 2019 The USPSTF recommends prophylactic ocular topical medication for all newborns to prevent gonococcal ophthalmia neonatorum. Osteoporosis Screening USPSTF "B" Recommendation June 2018 The USPSTF recommends screening for	77081, 78350, 78351,	Payable with a diagnosis code in
Medication USPSTF "A" Recommendation January 2019 The USPSTF recommends prophylactic ocular topical medication for all newborns to prevent gonococcal ophthalmia neonatorum. Osteoporosis Screening USPSTF "B" Recommendation June 2018 The USPSTF recommends screening for osteoporosis with bone measurement testing	77081, 78350, 78351,	Payable with a diagnosis code in
USPSTF "A" Recommendation January 2019 The USPSTF recommends prophylactic ocular topical medication for all newborns to prevent gonococcal ophthalmia neonatorum. Osteoporosis Screening USPSTF "B" Recommendation June 2018 The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women 65 years and older.	77081, 78350, 78351,	Payable with a diagnosis code in
Medication USPSTF "A" Recommendation January 2019 The USPSTF recommends prophylactic ocular topical medication for all newborns to prevent gonococcal ophthalmia neonatorum. Osteoporosis Screening USPSTF "B" Recommendation June 2018 The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women	77081, 78350, 78351,	Payable with a diagnosis code in
Medication USPSTF "A" Recommendation January 2019 The USPSTF recommends prophylactic ocular topical medication for all newborns to prevent gonococcal ophthalmia neonatorum. Osteoporosis Screening USPSTF "B" Recommendation June 2018 The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women 65 years and older. The USPSTF recommends screening for	77081, 78350, 78351,	Payable with a diagnosis code in
USPSTF "A" Recommendation January 2019 The USPSTF recommends prophylactic ocular topical medication for all newborns to prevent gonococcal ophthalmia neonatorum. Osteoporosis Screening USPSTF "B" Recommendation June 2018 The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women 65 years and older. The USPSTF recommends screening for osteoporosis with bone measurement testing	77081, 78350, 78351,	Payable with a diagnosis code in
USPSTF "A" Recommendation January 2019 The USPSTF recommends prophylactic ocular topical medication for all newborns to prevent gonococcal ophthalmia neonatorum. Osteoporosis Screening USPSTF "B" Recommendation June 2018 The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women 65 years and older. The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in	77081, 78350, 78351,	Payable with a diagnosis code in

clinical risk assessment tool.		
Perinatal Depression: Preventive Interventions USPSTF "B" Recommendation February 2019 The USPSTF recommends that clinicians provide or refer pregnant and postpartum persons who are at increased risk of perinatal depression to counseling interventions	99385,99386, 99387, 99395, 99396, 99397, 99401, 99402, 99403, 99404, 96160, 96161, G0444	Payable with a diagnosis code in Diagnosis List 1
Phenylketonuria in Newborns Screening USPSTF "A" Recommendation March 2008 The USPSTF recommends screening for phenylketonuria in newborns.	84030, 99381, S3620	Procedure codes 84030 and S3620 reimbursable at the preventive level for children 0-90 days old
Prediabetes and Type 2 Diabetes Screening USPSTF "B" Recommendation August 2021 The USPSTF recommends screening for prediabetes and type 2 diabetes in adults aged 35 to 70 years who have overweight or obesity. Clinicians should offer or refer patients with prediabetes to effective preventive interventions.	82947, 82948, 82950, 82951, 83036, 82952, 97802, 97803, 97804, 99401, 99402, 99403, 99404, G0270, G0271, G0447, G0473, S9470	Payable with a diagnosis code in Diagnosis List 1
Preeclampsia Screening USPSTF "B" Recommendation April 2017 The USPSTF recommends screening for preeclampsia in pregnant women with blood pressure measurements throughout pregnancy.		Preeclampsia screening is done through routine blood pressure measurements
Rh(D) Incompatibility Screening USPSTF "A" Recommendation February 2004 The USPSTF strongly recommends Rh(D) blood typing and antibody testing for all pregnant women during their first visit for pregnancy-related care. USPSTF "B" Recommendation February 2004 The USPSTF recommends repeated Rh(D) antibody testing for all unsensitized Rh(D)- negative women at 24 to 28 weeks' gestation, unless the biological father is known to be	80055, 86850, 86870, 86900, 86901, 36415	Payable with a pregnancy diagnosis

Rh(D)-negative.		
Sexually Transmitted Infections Behavioral Counseling USPSTF "B" Recommendation August 2020 The USPSTF recommends behavioral counseling for all sexually active adolescents and for adults who are at increased risk for sexually transmitted infections (STIs). Refer also to HRSA's 'Sexually Transmitted Infections Counseling' recommendation	99384, 99385, 99386, 99387, 99394, 99395, 99396, 99397, 99401, 99402, 99403, 99404, 99411, 99412, G0445	
Sickle Cell Disease (Hemoglobinopathies) in Newborns Screening USPSTF "A" Recommendation September 2007 The USPSTF recommends screening for sickle cell disease in newborns.	83020, 83021, 83030, 83033, 83051, 85004, 85013, 85014, 85018, 85025, 85027, 99381, G0306, G0307, S3620, S3850	
Skin Cancer Counseling USPSTF "B" Recommendation March 2018 The USPSTF recommends counseling young adults, adolescents, children, and parents of young children about minimizing exposure to ultraviolet (UV) radiation for persons aged 6 months to 24 years with fair skin types to reduce their risk of skin cancer.	There are no procedure codes specific to skin cancer counseling.	
Statin Use for the Primary Prevention of Cardiovascular Disease in Adults Preventive Medication USPSTF "B" Recommendation August 2022 The USPSTF recommends that clinicians prescribe a statin for the primary prevention of CVD for adults aged 40 to 75 years who have 1 or more CVD risk factors (i.e. dyslipidemia, diabetes, hypertension, or smoking) and an estimated 10-year risk of a cardiovascular event of 10% or greater.	80061, 82465, 83700, 83718, 83719, 83721, 84478	For details about pharmacy benefit coverage, contact the number on the patient's BCBS member card. A patient's pharmacy benefit may be managed by a company other than BCBS. Coverage includes atorvastatin 10 mg and 20 mg, lovastatin 20 mg and 40 mg tablets, pravastatin 10 mg, 20 mg, 40 mg, and 80 mg tablets for members ages 40 – 75 years of age with a prescription.

Syphilis Infection in Nonpregnant Adults and Adolescents Screening	86592, 86780, 0065U	Payable with a diagnosis code in Diagnosis List 1
USPSTF "A" Recommendation June 2016 The USPSTF recommends screening for syphilis infection in persons who are at increased risk for infection.		
Syphilis Infection in Pregnant Women Screening USPSTF "A" Recommendation September 2018 The USPSTF recommends early screening for syphilis infection in all pregnant women.	80055, 80081, 86592, 86593, 86780, 0065U, 36415	Payable with a pregnancy diagnosis or a diagnosis code in Diagnosis List 1
Tobacco Smoking Cessation in Adults, Including Pregnant Women: Behavioral and Pharmacotherapy Interventions USPSTF "A" Recommendation January 2021 The USPSTF recommends that clinicians ask all adults about tobacco use, advise them to stop using tobacco, and provide behavioral interventions and U.S. Food and Drug Administration (FDA)—approved pharmacotherapy for cessation to adults who use tobacco. USPSTF "A" Recommendation January 2021 The USPSTF recommends that clinicians ask all pregnant women about tobacco use, advise them to stop using tobacco, and provide behavioral interventions for cessation to pregnant women who use tobacco.	99401, 99402, 99403, 99404, 99406, 99407, G9016, S9453	For details about pharmacy benefit coverage, contact the number on the patient's BCBS member card. A patient's pharmacy benefit may be managed by a company other than BCBS. Two 90-day treatment regimens per benefit period. The 90-day treatments are at the discretion of the provider working with the member Prescription required for both over-the-counter (OTC) and prescription medications. Coverage includes: Generic bupropion hcl (smoking deterrent) ER 12hr 150 mg tablets Generic nicotine polacrilex 2 mg and 4 mg gum Generic nicotine polacrilex 2 mg and 4 mg lozenges

		 Generic nicotine 24hr 7 mg, 14 mg, and 21 mg transdermal patches Generic varenicline tartrate 0.5 mg and 1 mg tablets Brand Nicotine Transdermal Systems Brand Nicotrol Inhaler Brand Nicotrol Nasal Spray
Tobacco Use in Children and Adolescents Primary Care Interventions USPSTF "B" Recommendation April 2020 The USPSTF recommends that primary care clinicians provide interventions, including education or brief counseling, to prevent initiation of tobacco use among school-aged children and adolescents.	99401, 99402, 99403, 99404, 99406, 99407, G9016, S9453	Refer to Preventive Services Recommendation for Tobacco Smoking Cessation in Adults, Including Pregnant Women: Behavioral and Pharmacotherapy Interventions
Screening for Unhealthy Drug Use USPSTF "B" Recommendation June 2020 The USPSTF recommends screening by asking questions about unhealthy drug use in adults age 18 years or older. Screening should be implemented when services for accurate diagnosis, effective treatment, and appropriate care can be offered or referred.	99385, 99386, 99387, 99395, 99396, 99397, 99408, 99409, G0396, G0397	Payable with a diagnosis code in Diagnosis List 1
Vision Screening in Children USPSTF "B" Recommendation September 2017 The USPSTF recommends vision screening at least once in all children aged 3 to 5 years to detect amblyopia or its risk factors.	99172, 99173, 0333T	
General Lab Panel These lab codes could be multiple Preventive	80050, 80053	Payable with a diagnosis code in Diagnosis List 1

Services recommendations

HRSA Recommendations:

Service:	Procedure	Additional
	Code(s):	Reimbursement Criteria:
Anxiety Screening HRSA Recommendation December 2019 The Women's Preventive Services Initiative recommends screening for anxiety in adolescent and adult women, including those who are pregnant or postpartum.	96127, 99384, 99385, 99386, 99387, 99394, 99395, 99396, 99397, G0444	Procedure code 96127 is only reimbursable at the preventive level when billed with a diagnosis of Z00.129, Z13.31, Z13.32, Z13.39, Z13.41, or Z13.42
Breast Cancer Screening for Women at Average Risk HRSA Recommendation December 2019 The Women's Preventive Services Initiative recommends that average-risk women initiate mammography screening no earlier than age 40 and no later than age 50. Screening mammography should occur at least biennially and as frequently as annually. Screening should continue through at least age 74 and age alone should not be the basis to discontinue screening. These screening recommendations are for women at average risk of breast cancer. Women at increased risk should also undergo periodic mammography screening, however, recommendations for additional services are beyond the scope of this recommendation Refer also to USPSTF's 'Breast Cancer Screening' recommendation	77061, 77062, 77063, 77065, 77066, 77067, G0279	Payable with a diagnosis code in Diagnosis List 1
Breastfeeding Services and Supplies	E0602, E0603,	Electric breast pumps limited to
	E0604, A4281,	one per benefit period. Hospital
HRSA Recommendation December 2019	A4282, A4283,	Grade breast pumps are limited to
The Women's Preventive Services Initiative	A4284, A4285,	rental only.
recommends comprehensive lactation support	A4286, S9443,	
services (including counseling, education, and	99401, 99402,	Additional reimbursement
breastfeeding equipment and supplies) during	99403, 99404,	information available within the

the antenatal, perinatal, and the postpartum	99411, 99412,	"Breastfeeding Equipment and
period to ensure the successful initiation and	99347, 99348,	Supplies" Coverage
maintenance of breastfeeding.	99349, 99350	
Refer also to USPSTF's 'Breastfeeding Primary		
Care Interventions' recommendation		
Cervical Cancer Screening	0096U, 0500T,	Payable with a diagnosis code in
	87623, 87624,	Diagnosis List 1
HRSA Recommendation December 2019	87625, 88141,	
The Women's Preventive Services Initiative	88142, 88143,	
recommends cervical cancer screening for	88147, 88148,	
average-risk women aged 21 to 65 years. For	88150, 88152,	
women aged 21 to 29 years, the Women's	88153, 88155,	
Preventive Services Initiative recommends	88164, 88165,	
cervical cancer screening using cervical	88166, 88167,	
cytology (Pap test) every 3 years. Cotesting	88174, 88175,	
with cytology and human papillomavirus	99385, 99386,	
testing is not recommended for women	99387, 99395,	
younger than 30 years. Women aged 30 to 65	99396, 99397,	
years should be screened with cytology and	G0101, G0123,	
human papillomavirus testing every 5 years or	G0124, G0141,	
cytology alone every 3 years. Women who are	G0143, G0144,	
at average risk should not be screened more	G0145, G0147,	
than once every 3 years.	G0148, G0476,	
	P3000, P3001,	
Refer also to USPSTF 'Cervical Cancer	Q0091, S0610,	
Screening' recommendation	S0612	
Contraceptive Methods and Counseling	57170, 58300,	Contracention methods that
Contraceptive iviethous and counseling	58301, 58600,	Contraception methods that require a prescription may be
LIDEA Pasammandation December 2010	58605, 58611,	covered under the patient's
HRSA Recommendation December 2019 The Women's Proventive Services Initiative		1
The Women's Preventive Services Initiative	58615, 58661, 58565, 58670,	medical or pharmacy benefit. For details about pharmacy benefit
recommends that adolescent and adult	58671, 58340,	coverage for contraception,
women have access to the full range of	74740, 88302,	contact the number on the
female-controlled contraceptives to prevent	88305, 96372,	patient's BCBS member card. A
unintended pregnancy and improve birth	11976, 11981,	patient's pharmacy benefit may be
outcomes. Contraceptive care should include	11976, 11981,	managed by a company other
contraceptive counseling, initiation of contraceptive use, and follow-up care (e.g.,	A4261, A4264,	than BCBS.
management, and evaluation as well as	A4261, A4264, A4266, A4268,	than bebs.
changes to and removal or discontinuation of	A4269, J1050,	Visits pertaining to contraceptive
the contraceptive method). The Women's	J7296, J7297, J7298,	counseling, initiation of
Preventive Services Initiative recommends	J7300, J7301, J7303,	contraceptive use, and follow-up
that the full range of female-controlled U.S.	J7304, J7306, J7307,	care may also apply to procedure
Food and Drug Administration-approved	S4981, S4989,	codes under HRSA's 'Well-Woman'
contraceptive methods, effective family	3 7 301, 3 7 303,	recommendation
planning practices, and sterilization		recommendation
pianning practices, and sternization		

procedures be available as part of		Procedure code 58340
contraceptive care. The full range of		reimbursable at the preventive
contraceptive methods for women currently		level only when accompanied with
identified by the U.S. Food and Drug		modifier 33 or one of the
Administration include: (1) sterilization		following diagnosis codes: Z30.2,
surgery for women, (2) surgical sterilization via		Z30.40, Z30.42, Z30.49, Z98.51,
implant for women, (3) implantable rods, (4)		
copper intrauterine devices, (5) intrauterine		Procedure codes 11981, 11982,
devices with progestin (all durations and		and 11983 (are covered only when
doses), (6) the shot or injection, (7) oral		FDA approved contraceptive
contraceptives (combined pill), 8) oral		implant insertion or removal are
contraceptives (progestin only, and), (9) oral		performed) are reimbursable at
contraceptives (extended or continuous use),		the preventive level when billed
(10) the contraceptive patch, (11) vaginal		with one of the following
contraceptive rings, (12) diaphragms, (13)		diagnosis codes: Z30.013, Z30.017,
contraceptive sponges, (14) cervical caps, (15)		Z30.018, Z30.019, Z30.09, Z30.40,
female condoms, (16) spermicides, and (17)		Z30.42, Z30.46, Z30.49, Z30.8,
emergency contraception (levonorgestrel),		Z30.9
and (18) emergency contraception (ulipristal		
acetate), and additional methods as identified		Procedure code 58661
by the FDA. Additionally, instruction in		reimbursable at the preventive
fertility awareness-based methods, including		level with a diagnosis of Z30.2
the lactation amenorrhea method, although		G
less effective, should be provided for women		For details about pharmacy
desiring an alternative method.		benefit coverage, contact the
		number on the patient's BCBS
		member card. A patient's
		pharmacy benefit may be
		managed by a company other
		than BCBS.
		Prescription required for both
		over-the-counter (OTC) and
		prescription medications. For the
		list of contraceptive methods that
		may be covered, visit your health
		plan website.
Diabetes Mellitus Screening after Pregnancy	82947, 82948,	Payable with a diagnosis code in
LIBSA B	82950, 82951,	Diagnosis List 1
HRSA Recommendation	83036	
December 2019		
The Women's Preventive Services Initiative		
recommends women with a history of		
gestational diabetes mellitus (GDM) who are		
not currently pregnant and who have not		
been previously diagnosed with type 2		
diabetes mellitus should be screened for		
diabetes mellitus. Initial testing should ideally		

occur within the first year postpartum and can be conducted as early as 4–6 weeks postpartum. Women with a negative initial postpartum screening test result should be rescreened at least every 3 years for a minimum of 10 years after pregnancy. For women with a positive postpartum screening test result, testing to confirm the diagnosis of diabetes is indicated regardless of the initial test (e.g., oral glucose tolerance test, fasting plasma glucose, or hemoglobin A1c). Repeat testing is indicated in women who were screened with hemoglobin A1c in the first 6 months postpartum regardless of the result. Gestational Diabetes HRSA Recommendation December 2019 The Women's Preventive Services Initiative recommends screening pregnant women for gestational diabetes mellitus after 24 weeks of gestation (preferably between 24 and 28 weeks of gestation) in order to prevent adverse birth outcomes. Screening with a 50 g oral glucose challenge test (followed by a 3-hour 100 g oral glucose tolerance test if results on the initial oral glucose challenge test are abnormal) is preferred because of its high sensitivity and specificity. The Women's Preventive Services Initiative suggests that women with risk factors for diabetes mellitus be screened for preexisting diabetes before 24 weeks of gestation—ideally at the first prenatal visit, based on current clinical best practices. Refer also to USPSTF's 'Gestational Diabetes Mellitus Screening' recommendation	82947, 82948, 82950, 82951, 83036	Payable with a pregnancy diagnosis
Human Immune-Deficiency Virus Counseling & Screening HRSA Recommendation December 2019 The Women's Preventive Services Initiative recommends prevention education and risk assessment for human immunodeficiency	36415, 86689, 86701, 86702, 86703, 87389, 87390, 87391, 87806, G0432, G0433, G0435, G0475	Payable when billed with a diagnosis code in on Diagnosis List 1
virus (HIV) infection in adolescents and women at least annually throughout the lifespan. All women should be tested for HIV		

	1	
at least once during their lifetime. Additional		
screening should be based on risk, and		
screening annually or more often may be		
appropriate for adolescents and women with		
an increased risk of HIV infection. Screening		
for HIV is recommended for all pregnant		
women upon initiation of prenatal care with		
retesting during pregnancy based on risk		
factors. Rapid HIV testing is recommended for		
pregnant women who present in active labor		
with an undocumented HIV status. Screening		
during pregnancy enables prevention of		
vertical transmission.		
Refer also to USPSTF's 'Human		
Immunodeficiency Virus (HIV) Infection		
Screening for Pregnant and Non-Pregnant		
Adolescents and Adults' recommendation		
The state of the s		
Refer also to Bright Future's 'STI/HIV'		
Screening' recommendations		
Servering recommendations		
Interpersonal and Domestic Violence	99401, 99402,	
Screening	99403, 99404,	
	99411, 99412,	
HRSA Recommendation December 2019	99384, 99385,	
The Women's Preventive Services Initiative	99386, 99387,	
recommends screening adolescents and	99394, 99395,	
women for interpersonal and domestic	99396, 99397,	
violence at least annually, and, when needed,	99202, 99203,	
providing or referring for initial intervention	99204, 99205,	
services. Interpersonal and domestic violence	99211, 99212,	
includes physical violence, sexual violence,	99213, 99214,	
stalking and psychological aggression	99215, 99417	
(including coercion), reproductive coercion,	33213, 33417	
neglect, and the threat of violence, abuse, or		
both. Intervention services include, but are		
not limited to, counseling, education, harm		
reduction strategies, and referral to		
appropriate supportive services.		
appropriate supportive services.		
Sexually Transmitted Infections Counseling	99401, 99402,	
Total and the control of the control	99403, 99404,	
HRSA Recommendation December 2019	99411, 99412,	
The Women's Preventive Services Initiative	99384, 99385,	
	JJJUT, JJJUJ,	
I recommends directed behavioral counseling		
recommends directed behavioral counseling	99386, 99387,	
by a health care provider or other	99386, 99387, 99394, 99395,	
	99386, 99387,	

increased risk for sexually transmitted		
infections (STIs). The Women's Preventive		
Services Initiative recommends that health		
care providers use a woman's sexual history		
and risk factors to help identify those at an		
increased risk of STIs. Risk factors may include		
age younger than 25, a recent history of an		
STI, a new sex partner, multiple partners, a		
partner with concurrent partners, a partner		
with an STI, and a lack of or inconsistent		
condom use. For adolescents and women not		
identified as high risk, counseling to reduce		
the risk of STIs should be considered, as		
determined by clinical judgement.		
Refer also to USPSTF's 'Sexually Transmitted		
Infections Behavioral Counseling'		
recommendation		
Urinary Incontinence Screening	There are no	Payable with a diagnosis code in
	procedure codes	Diagnosis List 1
HRSA Recommendation	specific to this	
December 2019	service. This service	
The Women's Preventive Services Initiative	would be part of the	
recommends screening women for urinary	preventive office	
incontinence annually. Screening should	visit.	
ideally assess whether women experience		
urinary incontinence and whether it impacts		
their activities and quality of life. The		
Women's Preventive Services Initiative		
recommends referring women for further		
evaluation and treatment if indicated. The		
Women's Preventive Services Initiative		
recommends screening women for urinary		
incontinence as a preventive service. Factors		
associated with an increased risk for urinary		
incontinence include increasing parity,		
advancing age, and obesity; however, these		
factors should not be used to limit screening.		
Several screening tools demonstrate fair to		
high accuracy in identifying urinary		
incontinence in women. Although minimum		
screening intervals are unknown, given the		
prevalence of urinary incontinence, the fact		
that many women do not volunteer		
symptoms, and the multiple, frequently-		
changing risk factors associated with		
incontinence, it is reasonable to conduct		

annually.		
Well-Woman Visits	99384, 99385,	Labs administered as part of a
	99386, 99387,	normal pregnancy reimbursable at
HRSA Recommendation December 2019	99394, 99395,	the preventive level when billed
The Women's Preventive Services Initiative	99396, 99397,	with a pregnancy diagnosis
recommends that women receive at least one	G0101, G0438,	
preventive care visit per year beginning in	G0439, 99078,	
adolescence and continuing across the	99401, 99402,	
lifespan to ensure that the recommended	99403, 99404,	
preventive services, including preconception,	99411, 99412,	
and many services necessary for prenatal and	99408, 99409,	
interconception care are obtained. The	G0396, G0442,	
primary purpose of these visits should be the	G0443, G0444	
delivery and coordination of recommended		
preventive services as determined by age and		
risk factors.		

ACIP Recommendations:

Service:	Procedure	Additional
	Code(s):	Reimbursement Criteria:
COVID-19 Vaccine	91300, 91301, 0001A, 0002A, 0003A, 0011A, 0012A, 0013A	
DTaP Vaccine	90696, 90698, 90700, 90702, 90723	
Hepatitis A Vaccine	90632, 90633, 90634, 90636	
Hepatitis B Vaccine	90739, 90740, 90743, 90744, 90746, 90747, 90748, 90759	Hepatitis B Vaccination is payable at the preventive level for newborns under 90 days of age when obtained in the inpatient setting from an in-network provider
Haemophilus Influenzae Type B (Hib) Vaccine	90647, 90648	

Human Papillomavirus Vaccine (HPV)	90649, 90650, 90651	Payable with a diagnosis code in Diagnosis List 1
Influenza Vaccine	90630, 90653, 90654, 90655, 90656, 90657, 90658, 90660, 90661,90662, 90666, 90667, 90668, 90672, 90673, 90674, 90682, 90685, 90686, 90687, 90688, 90689, 90694, 90756 Q2034, Q2035, Q2036, Q2037, Q2038, Q2039	
Measles, Rubella, Congenital Rubella Syndrome, and Mumps (MMR)	90707	
Measles, Mumps, Rubella, and Varicella (MMRV)	90710	
Meningococcal Vaccine	90644, 90733, 90734, 90619, 90620, 90621	
Pneumococcal Vaccine	90670, 90677, 90732	
Polio Vaccine	90713	
Rotavirus Vaccine	90680, 90681	
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (Tdap/Td)	90714, 90715	
Varicella Vaccine	90716	
Zoster (Shingles) Vaccine	90736, 90750	
Immunization Administration	90460, 90461, 90471, 90472, 90473, 90474, 90749	

Bright Futures Recommendations:

Service:	Procedure	Additional
	Code(s):	Reimbursement Criteria:
Alcohol Use and Drug Use Assessment	99408, 99409	Payable with a diagnosis code in Diagnosis List 1
Bright Futures		
Recommends alcohol and drug use		
assessments for adolescents between the		
ages of 11 to 21 years		
Anemia Screening in Children	85014, 85018	Payable with a diagnosis code in Diagnosis List 1
Bright Futures		
Recommends anemia screening for children under the age of 21 years of age		For details about pharmacy benefit coverage, contact the number on the patient's BCBS member card. A patient's pharmacy benefit may be managed by a company other than BCBS.
		Prescription required for both over-the-counter (OTC) and prescription medications. Coverage provided for members up to 1 year of age.
Cervical Dysplasia Screening	Q0091	Payable with a diagnosis code in
Bright Futures Recommends cervical dysplasia screening for adolescents age 21 years of age		Diagnosis List 1
Critical Congenital Heart Defect Screening	94760	
Bright Futures Recommends screening for critical congenital heart disease using pulse oximetry for newborns after 24 hours of age, before discharge from the hospital		
Depression Screening	96110	Payable with a diagnosis code in
Bright Futures Recommends depression screening for adolescents between the ages of 11 to 21 years		Diagnosis List 1
	<u> </u>	

Refer also to USPSTF's 'Depression in Children and Adolescents Screening' recommendation		
Developmental Screening / Autism Screening Bright Futures Recommends developmental/autism screening for infants and young children between the ages of 9 months and 30 months	96110	Payable with a diagnosis code in Diagnosis List 1
Dyslipidemia Screening Bright Futures Recommends dyslipidemia screening for	80061, 82465, 83718, 84478	Payable with a diagnosis code in Diagnosis List 1
children and adolescents between the ages of 24 months and 21 years of age		
Hearing Screening Bright Futures Recommends hearing screenings for children and adolescents from birth through 21 years of age	92558, 92567, 92551, 92650, 92651, 92652, 92653, V5008	Procedure codes 92558, 92567, 92551, V5008 are payable at the preventive level only when billed with diagnosis codes Z01.10, Z01.118, and Z01.11 for ages 22 and under.
		Eff. 01/01/2021 CPT codes 92650, 92651, 92652, 92653 may be payable at the preventive level only when billed with diagnosis codes Z01.10, Z01.118, and Z01.11 through ages 22 and under, if meeting Medical Policy criteria.
Hematocrit or Hemoglobin Bright Futures Recommends hematocrit or hemoglobin screening for children and adolescents between the ages of four months and 21 years of age	36415, 36416, 85014, 85018	Payable with a diagnosis code in Diagnosis List 1
HIV Screening	87389, 87390, 87391, 87806, G0432, G0433, G0435	Payable with a diagnosis code in Diagnosis List 1
Lead Screening Bright Futures	36415, 36416, 83655	Payable with a diagnosis code in Diagnosis List 1
Recommends screening children between the		

ages of six months and six years for lead		
Maternal Depression Screening	99384, 99385, 99386, 99387, 99394, 99395, 99396, 99397, G0444	
Newborn Bilirubin	82247, 82248, 88720	Payable with a diagnosis in Diagnosis List 1
Newborn Blood Screening	\$3620	Payable with a diagnosis code in Diagnosis List 1
Oral Health Bright Futures Recommends oral health risk assessments beginning at six months of age	99211, 99212, 99188, 99381, 99382, 99383, 99384	Payable with a diagnosis code in Diagnosis List 1
Prenatal Visit	99401, 99402, 99403, 99404	Payable with a diagnosis code in Diagnosis List 1
Preventive Medicine Services: New Patients	99381, 99382, 99383, 99384, 99385	Payable with a diagnosis code in Diagnosis List 1
Preventive Medicine Services: Established Patients	99391, 99392, 99393, 99394, 99395	Payable with a diagnosis code in Diagnosis List 1
Bright Futures Recommends screening for all sexually active patients Refer also to USPSTF's 'Human Immunodeficiency Virus (HIV) Infection Screening for Pregnant and Non-Pregnant Adolescents and Adults' recommendations Refer also to HRSA's 'Sexually Transmitted Infections Counseling' recommendation	86631, 86632, 86701, 86703, 87081, 87110, 87210, 87270, 87320, 87490, 87491, 87590, 87591, 87800, 87801, 87810, 87850, 36415	Payable with a diagnosis code in Diagnosis List 1
Tuberculosis Testing Bright Futures Recommends tuberculosis testing if the risk assessment is positive	86580, 99211	Payable with a diagnosis code in Diagnosis List 1
Vision Screening Bright Futures	99173	Payable with a diagnosis code in Diagnosis List 1

Recommends vision screening for newborns	
through age 21 years	

Many of the services listed above may be performed for indications other than preventive care. In these situations, services may be covered by another provision of the individual's benefit plan and subject to applicable cost sharing.

Diagnosis List 1

Z00.00	Z00.01	Z00.110	Z00.111	Z00.121	Z00.129	Z00.8
Z01.411	Z01.419	Z02.83	Z11.1	Z11.3	Z11.4	Z11.51
Z11.7	Z12.11	Z12.12	Z12.2	Z12.31	Z12.39	Z12.4
Z12.5	Z13.0	Z13.1	Z13.220	Z13.31	Z13.32	Z13.4
Z13.41	Z13.42	Z13.5	Z13.6	Z13.820	Z20.2	Z20.6
Z23	Z30.011	Z30.012	Z30.013	Z30.014	Z30.015	Z30.016
Z30.017	Z30.018	Z30.019	Z30.02	Z30.09	Z30.40	Z30.41
Z30.42	Z30.430	Z30.431	Z30.432	Z30.433	Z30.44	Z30.45
Z30.46	Z30.49	Z30.8	Z30.9	Z32.2	Z71.41	Z71.51
Z71.6	Z71.7	Z71.82	Z71.83	Z86.32	Z97.5	R73.03

Breastfeeding Equipment & Supplies

Non-grandfathered plans provide coverage of manual, electric, and hospital grade breast pumps along with breastfeeding supplies at the preventive level.

Manual breast pumps utilize procedure code E0602 and are available for purchase and covered at the preventive level when obtained In-Network, Out of Network, or from Retail providers. Sales tax is excluded from retail purchases.

Electric breast pumps utilize procedure code E0603 and must be rented or purchased from an In-Network provider or a contracted durable medical equipment supplier. The models of breast pumps being provided at the preventive level are up to the individual provider's discretion. If a member chooses to obtain an upgraded model, they may be balance billed the difference between the allowance of the standard model and the cost of the upgraded model. Members are allowed one electric breast pump per benefit period.

*Note: Retail providers such as Target, Wal-Mart, or online vendor are not licensed medical providers and therefore are considered Out of Network. Out of network coverage will follow the out of network benefit level for preventive services. This may include cost sharing and sales tax is excluded. *

Hospital grade breast pumps utilize procedure code E0604 and are only covered when rented In-Network or from an In-Network durable medical equipment supplier. Hospital grade breast pump

coverage is up to the purchase price of \$1,000.00 or 12 months, whichever comes first. At the end of coverage, the unit must be returned to the durable medical equipment supplier. Members are allowed one breast pump per benefit period.

Breast pumps obtained from Out of Network providers are reimbursable at the Out of Network level.

The following breast pump supplies are reimbursable at the preventive level. Some limitations and restrictions may apply based on the group coverage for preventive services.

- A4281- Tubing for breast pump, replacement, spare membranes, replacements
- A4282- Adapter for breast pump, replacement
- A4283- Cap for breast pump bottle, replacement
- A4284- Breast shield and splash protector for use with breast pump, replacement
- A4285- Polycarbonate bottle for use with breast pump, replacement
- A4286- Locking ring for breast pump, replacement

<u>Differentiating Preventive Care versus Diagnostic Care</u>

The following types of services are considered Preventive:

- Screenings intended to prevent illness or identify issues before symptoms are evident
- Counseling intervention as defined by a specific preventive recommendation

Examples of preventive services:

- A 60-year-old woman obtains her biennial mammogram to screen for breast cancer
- A patient who has been identified as having cardiovascular disease risk factors is referred for nutritional counseling
- A 50-year-old patient obtains a colonoscopy to screen for colorectal cancer
- A 42-year-old patient goes to their doctor for their annual physical and receives a blood test to screen for abnormal blood glucose

The following types of services are considered Diagnostic:

- The diagnosis of existing symptoms or abnormalities
- Treatment for specific health conditions, ongoing care, or other tests to manage a health condition

Examples of diagnostic services:

- A 60-year-old woman obtains a mammogram after noticing a lump in her breast
- A patient diagnosed with diabetes is referred for nutritional counseling to manage their condition

• A patient goes to their doctor for their annual physical and receives a blood test to check iron and liver function, and a urinalysis is requested

Limitations and Exclusions

- 1. <u>Services not reimbursable at the preventive level may be reimbursable under another portion of</u> the medical plan.
- 2. Breastfeeding equipment and supplies not listed underneath the "Breastfeeding Equipment and Supplies" section. This includes, but is not limited to
 - a. Batteries
 - b. Breastfeeding ointments, creams
 - c. Breast milk storage supplies including bags, freezer packs, etc.
 - d. Breast pump cleaning supplies
 - e. Breast pump traveling cases
 - f. Infant scales
 - g. Nursing bras
 - h. Nursing covers, scarfs
- 3. Immunizations that are not published in the Center for Disease Control's Morbidity and Mortality Weekly Report (MMWR) and/or are not on the list of "Vaccines Licensed for Use in the United States" by the United States Food and Drug Administration (FDA).
- 4. Prescription coverage may vary depending on the terms and conditions of the plans. A prescription may be required for coverage under the pharmacy benefit. The plan may also require that the generic drug be tried first before the brand version. Age limits, restrictions, and other requirements may apply. Members can verify their pharmacy benefits by calling the customer service number on the back of their ID card.
- 5. For OTC purchases, members will need to obtain a prescription from their provider and take it to the pharmacy to be filled.
- 6. Exceptions may apply, members can verify their pharmacy benefits by calling the customer service number on the back of their ID card.
- 7. If there is a medication not included, the member should consult their doctor for therapeutic alternatives first before submitting coverage exceptions to BCBS.

Each benefit plan, summary plan description or contract defines which services are covered, which services are excluded, and which services are subject to dollar caps or other limitations, conditions or exclusions. Members and their providers have the responsibility for consulting the member's benefit plan, summary plan description or contract to determine if there are any exclusions or other benefit limitations applicable to this service or supply. If there is a discrepancy between a MEDICAL POLICY and a member's benefit plan, summary plan description or contract, the benefit plan, summary plan description or contract will govern.

References:

Advisory Committee on Immunization Practices (ACIP). "Vaccine-Specific ACIP Recommendations." Retrieved March 1, 2022, from https://www.cdc.gov/vaccines/hcp/acip-recs/index.html

American Academy of Pediatrics- Bright Futures. "Coding for Pediatric Preventive Care, 2022."

Retrieved March 1, 2022, from https://www.aap.org/en-us/Documents/coding preventive care.pdf

American Academy of Pediatrics - Bright Futures. "Recommendations for Preventive Pediatric Health Care." Retrieved March 1, 2022, from https://www.aap.org/en-us/Documents/periodicity_schedule.pdf

American Academy of Pediatrics- Bright Futures. "Achieving Bright Futures."

Retrieved March 1, 2022, from https://www.aap.org/en-us/Documents/practicet_periodicity_AllVisits.pdf

Centers for Disease Control and Prevention. "Immunization Schedules."

Retrieved March 1, 2022, from https://www.cdc.gov/vaccines/schedules/index.html

Health Resources and Services Administration. "Women's Preventive Services Guidelines." Retrieved March 1, 2022, from https://www.hrsa.gov/womens-guidelines-2019

United States Food and Drug Administration. "Vaccines Licensed for Use in the United States." Retrieved March 1, 2022,

https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833

United States Preventive Services Task Force. "Published Recommendations." Retrieved March 1, 2022, from

https://www.uspreventiveservicestaskforce.org/BrowseRec/Index/browse-recommendations

Policy Update History:

Approval Date	Description
06/23/2017	New policy, replaces medical policy ADM1001.030
07/14/2017	Removed codes 99174 and 99177.
12/06/2017	Coding and USPSTF updates
04/30/2018	Coding and USPSTF updates
07/12/2018	Coding and USPSTF updates
12/27/2018	Coding and USPSTF updates
09/26/2019	Coding and USPSTF updates
10/14/2019	HPV vaccine update
12/30/2019	Disclaimer, Coding and USPSTF updates
04/20/2020	Recommendation updates
06/08/2020	Disclaimer, Coding, Links, and recommendation updates

09/09/2020	Coding and recommendation updates
12/21/2020	Coding and recommendation updates, drug information updates and
	disclaimers
1/12/2021	Coding updates
9/22/2021	Coding and recommendation updates, drug information updates
12/16/2021	Coding and USPSTF updates
03/23/2022	Coding and recommendation updates
06/01/2022	Coding and recommendation updates
07/29/2022	Diagnosis List 1 updates
09/09/2022	Coding and recommendation updates

The Plan makes no endorsement, representations or warranties regarding any products or services offered by independent third-party vendors such as Target and Wal-Mart. These vendors are solely responsible for the products and services they offer. If you have any questions about the products or services offered by such vendors, you should contact the vendor(s) directly.